Anagnostou Elli, Mavrogianni Despina, Prifti Ilectra-Niki, Dimitroulia Evangelia, Protopapas Athanasios, Drakakis Peter, Loutradis Dimitrios
1st Department of Obstetrics and Gynecology, Division of Human Reproduction, IVF Unit, Alexandra Hospital, Medical School of National Kapodistrian University of Athens, Athens, Greece.
Int J Reprod Med. 2021 Feb 9;2021:8685158. doi: 10.1155/2021/8685158. eCollection 2021.
Several studies have investigated on the polymorphism Ser680Asn of FSHR and its use as a predictive indicator of response to an IVF/ICSI protocol. Furthermore, measurement of AMH in serum and follicular fluid is a useful prognostic indicator for the outcome of an assisted reproduction attempt. The purpose of this study is to examine the FSH receptor Ser680Asn polymorphism in combination with AMH levels in both serum and follicular fluid, on the day of oocyte collection.
A total of 32 women who underwent IVF/ICSI were included. Women were grouped into 2 groups: those who received rFSH ( = 11) and those who received hMG ( = 21). Serum AMH was measured on day 3 of the cycle, and AMH in the follicular fluid on the day of oocyte retrieval; the same day peripheral blood was collected for the genotyping of Ser680Asn.
No statistical significant difference was found between serum AMH and follicular fluid AMH regarding the FSH receptor genotype for the Ser680Asn polymorphism. Regarding the sAMH/ffAMH ratio in the 3 genotypes, the value was lower in Asn/Asn women than Ser/Ser and Ser/Asn, but no statistical difference was obtained. Women who carry the Ser allele have a higher number of follicles, retrieved oocytes, and mature oocytes than women who do not contain the Ser allele. Women with AMH < 2.22 ng/ml presented lower AMH follicular fluid levels and lower serum AMH/follicular fluid AMH ratio in a statistically significant manner. Concerning the genotype for the polymorphism Ser680Asn of FSHR in relation to AMH levels, no statistically significant differences were found.
The identification of polymorphisms, such as Ser680Asn of FSHR, along with the determination of endocrine markers in the follicular fluid, such as AMH, could lead at some point, to the personalized therapy setting per woman.
多项研究已对促卵泡激素受体（FSHR）的Ser680Asn多态性及其作为体外受精/卵胞浆内单精子注射（IVF/ICSI）方案反应预测指标的用途进行了调查。此外，血清和卵泡液中抗苗勒管激素（AMH）的测定是辅助生殖尝试结果的有用预后指标。本研究的目的是在取卵日检查FSH受体Ser680Asn多态性与血清和卵泡液中AMH水平的联合情况。
总共纳入了32例行IVF/ICSI的女性。女性被分为2组：接受重组促卵泡激素（rFSH）的女性（n = 11）和接受人绝经期促性腺激素（hMG）的女性（n = 21）。在月经周期第3天测量血清AMH，在取卵日测量卵泡液中的AMH；同一天采集外周血用于Ser680Asn的基因分型。
就Ser680Asn多态性的FSH受体基因型而言，血清AMH和卵泡液AMH之间未发现统计学显著差异。关于3种基因型中的血清AMH/卵泡液AMH比值，Asn/Asn女性的值低于Ser/Ser和Ser/Asn女性，但未获得统计学差异。携带Ser等位基因的女性比不携带Ser等位基因的女性有更多的卵泡、回收的卵母细胞和成熟卵母细胞。AMH < 2.22 ng/ml的女性卵泡液AMH水平较低，血清AMH/卵泡液AMH比值较低，差异具有统计学意义。关于FSHR的Ser680Asn多态性基因型与AMH水平的关系，未发现统计学显著差异。
识别多态性，如FSHR的Ser680Asn，以及测定卵泡液中的内分泌标志物，如AMH，在某个时候可能会导致针对每位女性的个性化治疗方案。
